ADI-212: PSMA-Targeted Allogeneic Gamma-Delta CAR T Cell Therapy Receives Phase 1 Clearance in mCRPC

KEY FINDINGS

• Regulatory decision: On 27 August 2026 the FDA cleared the IND (Investigational New Drug) application for ADI-212.
• Trial: A phase 1/2 trial (NCT07793435) will enrol patients with metastatic castration-resistant prostate cancer (mCRPC); enrolment is planned to begin in the fourth quarter of 2026.
• What makes the product different: ADI-212 differs structurally from autologous CAR T. It is an allogeneic, "off-the-shelf" product; it does not require separate manufacturing for each patient. The source cells are not alpha-beta T cells but gamma-delta 1 (Vδ1) T cells.
• Three layers of engineering: (1) a novel CAR binder recognising PSMA with high specificity, (2) "armouring" with membrane-bound IL-12, (3) silencing of the mediator complex subunit 12 (MED12) gene with CRISPR/Cas9.
• Preclinical data: In vitro cytotoxicity against 22Rv1 cells was superior to that of PSMA-targeted αβ CAR T cells; in PC3-PSMA xenograft models, a single intravenous dose produced durable tumour control and activity against contralateral tumour rechallenge on day 15.
• Design: 3+3 dose escalation, approximately 12 patients, single centre (Redwood City, California). The primary endpoints are safety-focused: MTD/MAD and the rate of treatment-related adverse events.
• A critical caution: These are not efficacy data. At this stage all we have is regulatory clearance and preclinical data; clinical response data will have to wait until 2028.

Background: Why Is Prostate Cancer Resistant to Immunotherapy?

While checkpoint inhibitors transformed the treatment paradigm in melanoma, non-small cell lung cancer and renal cell carcinoma, prostate cancer remained largely outside this revolution. The reasons are well defined: low tumour mutational burden, limited neoantigen diversity, a "cold" tumour microenvironment poor in T cell infiltration, dominance of regulatory T cells (Tregs) and myeloid-derived suppressor cells, and TGF-β-mediated immune suppression.

CAR T cell therapy produced striking results in haematological malignancies; but the same success has not been repeated in solid tumours. The obstacles are structural: heterogeneous expression of the target antigen, difficulty of effective migration and infiltration into the tumour, exhaustion of T cells in the microenvironment and the risk of off-target toxicity. In prostate cancer, PSMA is an almost ideal target by virtue of its expression profile - yet PSMA-targeted CAR T attempts have to date resulted in limited and transient responses.

ADI-212 is a product designed to give a separate engineering answer to each of these obstacles. For that reason, although it has not yet been given to any patient, it is conceptually noteworthy.

How Does ADI-212 Work? The Three Layers of the Design

1. Vδ1 gamma-delta T cells: an effector different from alpha-beta

Conventional CAR T products are manufactured from αβ T cells collected from the patient. ADI-212, by contrast, uses gamma-delta 1 (Vδ1) T cells obtained from healthy donors. This subset is a tissue-resident population that bridges innate and adaptive immunity and has the capacity for MHC-independent tumour recognition. There are two practical consequences: it is suitable for allogeneic use - because Vδ1 cells do not carry a risk of graft-versus-host disease (GvHD), an "off-the-shelf" product can be manufactured for many patients from a single donor; this removes the disadvantages of autologous CAR T such as weeks-long manufacturing, the risk of manufacturing failure and high cost. Second, it has a high tendency to tissue residence, providing a theoretical advantage in migration and infiltration into a solid tumour mass.

2. "Armouring" with membrane-bound IL-12

IL-12 is a potent cytokine that strengthens T cell and NK cell activation, drives a Th1 response and reprogrammes a suppressive microenvironment. However, because it causes serious toxicity when given systemically, its clinical use has been limited. In ADI-212, IL-12 is expressed in a membrane-tethered form; that is, it exerts its effect only in the local microenvironment where the CAR T cell is present. This is a design choice aimed at achieving intratumoural immune activation without systemic cytokine toxicity.

3. MED12 knockout with CRISPR/Cas9

MED12, a subunit of the mediator complex, plays a role in transcriptional regulation. Its silencing via CRISPR/Cas9 has emerged in preclinical studies as a strategy that increases the expansion capacity and persistence of CAR T cells. Resistance to exhaustion and long-lasting antitumour activity are the aims.

The Preclinical Evidence Base

Preclinical data presented at the 32nd Prostate Cancer Foundation Scientific Retreat in October 2025 formed the scientific basis of the IND application:

The result of the rechallenge experiment is particularly noteworthy. Demonstrating activity against a new tumour focus on the opposite side suggests persistence of the cells in the circulation and systemic antitumour memory. That said, it should not be forgotten that xenograft models mimic the human tumour microenvironment only partially and that results obtained in immunodeficient mice cannot be translated directly into clinical efficacy.

Phase 1/2 Study Design (NCT07793435)

Safety: The Real Subject of This Trial

All the primary endpoints of phase 1 are safety-focused, and this is a deliberate choice. The risks to be anticipated include cytokine release syndrome (which will be monitored particularly closely because of the IL-12 armouring), neurotoxicity (ICANS), cytopenias and infection risk arising from lymphodepletion, and on-target/off-tumour toxicity due to low-level expression of PSMA in the renal proximal tubules, small intestine and salivary glands. Although the new CAR binder is said to be designed to improve tolerability, this needs to be confirmed with human data.

Implications for Clinical Practice

1. No practical change today - but the direction matters

This is not an approval but a research clearance. It has not yet been given to any patient. It means no change in the current treatment algorithm for our mCRPC patients. Nevertheless, it is one of the developments signalling prostate cancer immunotherapy's emergence from the long lull that followed sipuleucel-T, and it shows that PSMA is now positioned not only as an imaging and radioligand target but also as a target for cell therapy.

2. Being "off-the-shelf" is decisive for clinical feasibility

In autologous CAR T therapies the interval between apheresis, manufacturing, quality control and infusion is often 3-6 weeks. In mCRPC patients with rapid progression this delay frequently eliminates the treatment opportunity. An allogeneic product resolves this logistical bottleneck in principle. Because of its scalability and cost profile, the product - if efficacy is proven - carries the potential to reach a far wider patient population.

3. The patient selection criteria foreshadow its future positioning

It is notable that the trial accepts patients who have received prior PSMA radioligand therapy (limited to a single course) while excluding other PSMA-targeted treatments. This reflects an intention to position ADI-212 as the next step in patients progressing after radioligand therapy - a genuine area of unmet need in the current algorithm.

4. Being measured in communication with our patients

News of this kind quickly turns into headlines about "new hope in prostate cancer" in the media. Our mCRPC patients and their families follow these headlines and ask about them in clinic. The correct message is this: science is moving in the right direction and prostate cancer research is more dynamic than ever; but this specific treatment has not yet begun its first human trial and does not affect today's treatment decisions. Nourishing hope while keeping expectations realistic is the foundation of patient trust.

Glossary

• CAR T cell therapy: A cell therapy produced by inserting an artificial receptor (chimeric antigen receptor) recognising a target on the tumour surface into the T cells of a patient or donor.
• Allogeneic / autologous: An allogeneic product is manufactured from a healthy donor and can be used in many patients; an autologous product is manufactured for each patient from their own cells.
• Vδ1 gamma-delta T cell: A tissue-resident T cell subset able to recognise tumours independently of MHC; it does not carry a risk of GvHD.
• Armouring: Making a CAR T cell express an additional immune-stimulating molecule (here, membrane-bound IL-12).
• IND: The research clearance obtained from the FDA in the United States to allow an investigational product to be tested in humans; it is not marketing approval.
• mCRPC: Metastatic castration-resistant prostate cancer.

Conclusion

The FDA's IND clearance for ADI-212 means that one of the technically most ambitious designs in prostate cancer cellular immunotherapy is moving into clinical evaluation. The combined use of an allogeneic Vδ1 platform, membrane-bound IL-12 armouring and CRISPR-mediated MED12 knockout is an attempt to respond simultaneously to three separate causes of CAR T failure in solid tumours - manufacturing logistics, the immunosuppressive microenvironment and cell exhaustion.

Conceptual elegance is not a guarantee of clinical efficacy. A phase 1 trial of approximately 12 patients will define the safety profile and determine the dose; efficacy signals can only be assessed in the expansion cohort and thereafter. Following this programme with scientific curiosity but at a cautious distance until 2028 will be the right approach.

References

• Clarke H. FDA greenlights phase 1 trial of ADI-212 in mCRPC. Urology Times. 28 August 2026.
• Feldman J. FDA Clears IND for ADI-212, a PSMA-Targeted CAR T, in mCRPC. Targeted Oncology. 29 August 2026.
• Adicet Bio, Inc. Adicet Bio Announces FDA Clearance of IND Application for ADI-212. Press release, 27 August 2026.
• ClinicalTrials.gov. A Phase 1/2 Trial of ADI-212 in mCRPC. NCT07793435. Last updated 28 August 2026.
• Herrman M, Murthy P, Ding B, et al. ADI-212: a next-generation gene-edited and armored allogeneic CAR γδ T cell therapy targeting PSMA for prostate cancer. Poster, Prostate Cancer Foundation Scientific Retreat; 25 October 2025.
• CancerNetwork. ADI-212 Receives FDA IND Clearance for Castration-Resistant Prostate Cancer. August 2026.